| Abstract | Methotrexate is easily administered, widely accepted by patients, and has a rapid therapeutic effect. With careful attention to known risk factors, such as alcoholism, diabetes, obesity, and renal disease, it is a useful agent for the treatment of refractory rheumatoid arthritis (RA). Although rheumatologists have been using methotrexate in the treatment of RA for some time, controlled studies have been needed to establish the safety and efficacy of this agent. This paper will review the findings of the Cooperating Clinics of the American Rheumatism Association, as well as other studies that have investigated the short term efficacy of methotrexate. |
| Authors | R F Willkens |
| Journal | The Journal of rheumatology. Supplement
(J Rheumatol Suppl)
Vol. 12 Suppl 12
Pg. 21-4
(Dec 1985)
ISSN: 0380-0903 CANADA |
| PMID | 3913772
(Publication Type: Clinical Trial, Journal Article, Review)
|
| Chemical References |
- Placebos
- Penicillamine
- Methotrexate
- Gold
|
| Topics |
- Arthritis, Rheumatoid
(drug therapy)
- Clinical Trials as Topic
- Double-Blind Method
- Drug Resistance
- Gold
(therapeutic use)
- Humans
- Immunosuppression
- Liver Diseases
(chemically induced)
- Methotrexate
(administration & dosage, adverse effects, therapeutic use)
- Pancytopenia
(chemically induced)
- Penicillamine
(therapeutic use)
- Placebos
- Psoriasis
(drug therapy)
|
